title: Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.
abstract: We aim to evaluate the efficacy and safety of paclitaxel-based doublet intravenous chemotherapy (IVC) with and without intraperitoneal chemotherapy (IPC) as the first-line treatment in advanced gastric cancer (AGC) with peritoneal metastasis (PM). 173 AGC patients with peritoneal metastasis were enrolled. All patients received paclitaxel-based doublet systemic chemotherapy Among them, 117 patients received IVC+IPC and 56 patients received IVC alone. The median OS of patients in the IP+ group was longer than the IP- group, however, there was no statistical difference between the two groups (11.1 months vs. 10.1 months, P = 0.072). In the multivariate analysis, the ECOG PS and IVC±IPC were independent prognostic factors for PFS and OS. There were no significant differences in the incidence of grade 3 and 4 toxicity between the IP+(DDP), IP+(FUDR) and IP- groups. Paclitaxel-based doublet regimens combining with IPC is effective, feasible and tolerated in AGC patients with PM.
authors.affiliation: Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching HospitalFuzhou, Fujian Province, People's Republic of China; Fujian Key Laboratory of Translational Cancer MedicineFuzhou, Fujian Province, People's Republic of China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University Zhenjiang, Jiangsu Province, People's Republic of China.
authors.forename: Wei-Feng
authors.initials: WF
authors.lastname: Tang
authors.affiliation: Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital Fuzhou, Fujian Province, People's Republic of China.
authors.forename: Jing
authors.initials: J
authors.lastname: Lin
authors.affiliation: Fujian Key Laboratory of Translational Cancer MedicineFuzhou, Fujian Province, People's Republic of China; Department of Molecular Pathology, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching HospitalFuzhou, Fujian Province, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Shi
authors.affiliation: Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital Fuzhou, Fujian Province, People's Republic of China.
authors.forename: Xiao-Jie
authors.initials: XJ
authors.lastname: Wang
authors.affiliation: Fujian Provincial Key Laboratory of Tumor BiotherapyFuzhou, Fujian Province, People's Republic of China; The Union Clinical Medical College of Fujian Medical UniversityFuzhou, Fujian Province, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching HospitalFuzhou, Fujian Province, People's Republic of China; Fujian Key Laboratory of Translational Cancer MedicineFuzhou, Fujian Province, People's Republic of China; Fujian Provincial Key Laboratory of Tumor BiotherapyFuzhou, Fujian Province, People's Republic of China.
authors.forename: Zeng-Qing
authors.initials: ZQ
authors.lastname: Guo
keywords: Advanced gastric cancer; intraperitoneal chemotherapy; intravenous chemotherapy; paclitaxel; peritoneal metastasis